Remdesivir is the first drug to show its effectiveness against COVID-19 in human trials (representational)
Gilead Sciences plans to prepare more than two million courses of its potential COVID-19 remdesivir by the end of the year and begin testing an easier-to-use inhaled version in August, the company announced on Monday. .
Remdesivir, which is currently administered intravenously, is the first drug to demonstrate efficacy against COVID-19 in human trials, and has been approved for emergency use by several countries, including the United States. United.
An inhaled formulation would be administered through a nebulizer, which could allow easier use outside of hospitals, said Gilead.
Gilead has entered into license agreements with nine generic manufacturers to increase the supply of remdesivir, said CEO Daniel O’Day in a statement.
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
